Entera Bio Ltd. appointed Geno J. Germano as Chairman of the Board effective February 4, 2026, succeeding Gerald Lieberman.123
Germano is a veteran pharmaceutical executive with over 30 years of experience, including senior roles at Pfizer leading a $14 billion innovative medicines portfolio.12
The appointment supports Entera Bio's upcoming milestones, including a Phase 3 registrational study for EB613 in osteoporosis and clinical testing for oral PTH in hypoparathyroidism in 2026.235
Entera Bio issued a press release on February 9, 2026, announcing the appointment.4
The company's stock has faced recent declines, trading around $1.21 after dropping significantly, amid pipeline progress and investor skepticism.23
Sources:
1. https://www.marketscreener.com/news/entera-bio-ltd-announces-board-changes-ce7e5aded08ef32d
2. https://www.nasdaq.com/articles/entera-bio-names-former-pfizer-executive-geno-j-germano-chairman
3. https://www.ainvest.com/news/entera-bio-chairman-appointment-catalyst-term-pipeline-progress-sign-distress-2602/
4. https://www.sec.gov/Archives/edgar/data/1638097/000117891326000355/zk2634303.htm
5. https://www.tradingview.com/news/financewire:0317ae0dd094b:0-entera-bio-attracts-former-pfizer-group-president-as-it-enters-a-new-phase-nasdaq-entx/